PRMT5 overexpression is involved in cell proliferation and survival in DLBCL and mantle cell lymphoma (MCL), as well as a variety of solid tumors including glioblastoma, lung carcinoma, melanoma, hepatocellular carcinoma (HCC), and colorectal cancer [26–32]. Here, PRMT5 is linked to diffuse large B-cell lymphoma.